Drugs & Targets Health Canada approves Keytruda + Inlyta for advanced RCC January 24, 2020Vol.46 No.04
Drugs & Targets 9/11 responders have increased overall cancer incidence in thyroid, prostate, and leukemia cancers, study finds January 24, 2020Vol.46 No.04
Drugs & Targets FDA grants Rubraca Priority Review for advanced prostate cancer January 17, 2020Vol.46 No.03
Drugs & Targets FDA accepts BLA for Priority Review of Opdivo + Yervoy in first-line NSCLC January 17, 2020Vol.46 No.03
Drugs & Targets Concerto HealthAI collaborates with Pfizer, Janssen; launches eurekaHealth 3.0 January 17, 2020Vol.46 No.03
Drugs & Targets Roche, Illumina collaborate to broaden patient access to genomic testing January 17, 2020Vol.46 No.03
Drugs & Targets Qiagen, Amgen collaborate on companion diagnostic development in NSCLC January 17, 2020Vol.46 No.03
Drugs & Targets FDA approves Keytruda for BCG-unresponsive, high-risk non-muscle invasive bladder cancer January 10, 2020Vol.46 No.02
Drugs & Targets FDA approves Ayvakit for unresectable or metastatic PDGFRA Exon 18 mutant gastrointestinal stromal tumor January 10, 2020Vol.46 No.02
Drugs & Targets Enfortumab vedotin gets FDA accelerated approval for advanced urothelial or bladder cancer January 10, 2020Vol.46 No.02
